Clinical Experiences
Residents are exposed
to a wide range of neurologic and neurosurgical cases, enabling them to gain experience
treating all types of diseases and disorders, including stroke, movement disorders,
epilepsy, sleep disorders, neuro-ophthalmologic problems, brain tumor, and also pediatric
patients with the above problems.
Established in 1992, the New Jersey Neuroscience Institute provides sophisticated tertiary
care services within a comfortable community hospital setting. Due to increased patient
volume, the Institute underwent extensive expansion and renovations in 1997, which added
testing and treatment rooms, state-of-the-art technology and instrumentation, three
research laboratories, clinical offices, a neuroscience library and conference room.
Facility and technology highlights include dedicated digital EEG rooms, a two-bed epilepsy
monitoring unit, a two-bed sleep lab, quantitative evoked potentials, ENG, posturography,
a vestibular rotary chair for balance testing and transcranial Doppler.
JFK Medical Center, a 441-bed institution, contains a 32-bed neuroscience unit, which
includes a two-bed video-EEG unit and a six-bed stroke unit. There is also a five-bed
pediatric special care unit. Fifty intensive care level beds in the medical and surgical
ICUs serve neurologic and neurosurgical patients. The medical center also provides
stereotactic radiosurgery , Gamma Knife, and radiation therapy, interventional
neuroradiology, extensive MRI capabilities, functional MRI, MR spectroscopy, diffusion and
perfusion imaging, and SPECT imaging. The affiliated JFK Johnson Rehabilitation Institute
has a 30-bed Brain Trauma Unit and 70 general rehabilitation beds, many of which serve
neurologic patients. There is also a 20-bed unit for patients with Huntington's disease at
the JFK Hartwyck Nursing, Convalescent and Rehabilitation Center at Cedar Brook.
Neurology also treat patients in JFK Medical Center's Emergency Medicine Department, where
they conduct clinical trials using tissue plasminogen activator (TPA) and
neuro-protectants to treat stroke patients.
 | ||||||||||||
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|||||||||||||||||||||||||||||||